4-Amino-2-(aryl)-butylbenzamides and their conformationally constrained analogues. Potent antagonists of the human neurokinin-2 (NK2) receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 13, 2003, Pages 2211-2215

  MacKenzie, A Roderick ^a,b   Marchington, Allan P ^a,c   Middleton, Donald S ^a   Newman, Sandra D ^a   Selway, Christopher N ^a   Terrett, Nicholas K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; AZETIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; NEUROKININ 2 RECEPTOR ANTAGONIST; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ARTICLE; CONFORMATION; DRUG POTENCY; SYNTHESIS;

EID: 0038548052     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00343-3     Document Type: Article

References (21)

1. Lecci A. Trends Pharmacol. Sci. 22:2001;551.
2. Gale J.D., O'Neill B.T., Humphrey J.M. Exp. Opin. Ther. Pat. 11:2001;1354.
3. Sakurada T., Sakurada C., Tan-No K., Kisara K. CNS Drugs. 8:1997;436.
4. Stout S.C., Owens M.J., Nemeroff C.B. Ann. Rev. Pharm. Toxicol. 41:2001;877.
5. Rogers D.F. Exp. Opin. Ther. Pat. 11:2001;1097. and references cited therein.
6. (a) Bushfield M., Metcalfe M., Naylor A.M. Br. J. Pharmacol. 115:1995;875
7. (b) Newgreen D.T. Emerg. Drugs. 3:1998;209.
8. (a) Advenier, C.; Edmonds-Alt, X.; Vilain, P.; Goulaouic, P.; Protietto, P.; Van Broeck, D.; Naline, E.; Le Fur, G.; Breliere, J. C. British Pharmacological Society Meeting, 1991, abstract C82.
9. (b) Edmonds-Alt, X.; Goulaouic, P.; Proietto, C.; van Broeck, D. European Patent 0 474 561 A1, 1991. (c) Edmonds-Alt X., Proietto P., Van Broeck D., Vilain P., Advenier C., Neliat G., Le Fur G., Breliere J.-C. Bioorg. Med. Chem. Lett. 3:1993;925 (d) Edmonds-Alt X., Vilain P., Proietto V., Van Broeck D., Naline E., Neliat G., Le Fur G., Breliere J.C. Life Sci. 50:1992;PL-101-PL-106.
10. For leading references see: (a) Gao Z., Peet N.P. Curr. Med. Chem. 6:1999;375 (b) Seward E.M., Swain C.J. Exp. Opin. Ther. Pat. 9:1999;571 (c) Swain C.J. Progress Med. Chem. 35:1998;57.
11. For leading references see: (a) Gao Z., Peet N.P. Curr. Med. Chem. 6:1999;375 (b) Seward E.M., Swain C.J. Exp. Opin. Ther. Pat. 9:1999;571 (c) Swain C.J. Progress Med. Chem. 35:1998;57.
12. For leading references see: (a) Gao Z., Peet N.P. Curr. Med. Chem. 6:1999;375 (b) Seward E.M., Swain C.J. Exp. Opin. Ther. Pat. 9:1999;571 (c) Swain C.J. Progress Med. Chem. 35:1998;57.
13. Tidwell T.T. Org. React. (N.Y.). 39:1990;297.
14. The synthesis and spectral data of all compounds has been reported previously. See: MacKenzie A.R., Marchington A.P., Middleton D.S., Meadows S.D. US Patent. 6:2001;242 438.
15. The synthesis and spectral data of 3-((N)-morpholino)azetidine has been reported previously. See: MacKenzie A.R., Marchington A.P., Meadows S.D., Middleton D.S. US Patent. 5:1996;963 923.
16. Bergstrom L., Beaujouan L.C., Torrens Y., Saffroy M., Glowinski J., Lavielle S., Chassaing G., Marguet A., D'Orleans-Juste P., Dion S. Mol. Pharmacol. 32:1987;764.
17. Patacchini R., Maggi C.A. Eur. J. Pharmacol. 236:1993;31.
18. 4-(2-imidazo)-4-hydroxy-piperidine used in the preparation of (1f) was prepared in two steps from commercially available N-benzylimidazole and N-benzylpiperidine-4-one, via 2-lithiation of the imidazole at -60°C in THF, followed by quenching with N-benzylpiperidine-4-one. Following work up and chromatography of the tertiary alcohol product, hydrogenolysis of the two N-benzyl groups was affected using 10% Pd/C under an atmosphere of hydrogen at 30 psi, 50°C for 4 h.
19. (a) The library was prepared by the reaction of the mesylate formed in Scheme 1 with substituted piperazines, piperidines and secondary alicyclic amines (86 reactants in total) using acetonitrile as solvent and heating the reaction mixtures in sealed reacti-vials™. The products were analysed by TLC and MS; the majority showed a single new product on TLC and the expected molecular ion by MS. (b) Selway C.N., Terrett N.K. Bioorg. Med. Chem. 4:1996;645.
20. MacKenzie A.R., Marchington A.P., Middleton D.S., Newman S.D., Jones B.C. J. Med. Chem. 45:2002;5365.
21. Goulaouic P., Edmonds-Alt X., Guele P., Proietto V. European Patent. 1992;512 901.